Sign inJoin waitlistJoin the waitlist

MM

Melissa Mark

Clinical Assistant Professor · Old Dominion University

Credentials: · · · · · ·

History

Old Dominion University
Present
Old Dominion University
Present

Pediatric Hematology Oncology
Cincinnati Children's Hospital Medical Center
2016–2018
Hospice and Palliative Medicine
Cincinnati Children's Hospital Medical Center
2015–2016
Pediatrics
Old Dominion University
2009–2012
Eastern Virginia Medical School
2005–2009

Research

Pain Prevalence and Treatment Patterns in a US Children's Hospital
Hospital Pediatrics · 2015 · Last of 3 authors · 59 citations
Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis
Pediatric Blood & Cancer · 2018 · 41 citations
Undifferentiated myxoid lipoblastoma with PLAG1-HAS2 fusion in an infant; morphologically mimicking primitive myxoid mesenchymal tumor of infancy (PMMTI)--diagnostic importance of…
Case report · Cancer Genetics · 2016 · 21 citations

Rachel Thienprayoon
2 papers
AN
Adam Nelson
1 paper · 1 as a resident
Alexander Boucher
1 paper
AM
Alison Mcgough-Maduena
1 paper · 1 as a fellow
AJ
Allison Jang
1 paper · 1 as a fellow
Allison Kay
1 paper · 1 as a fellow
Arun Gurunathan
1 paper · 1 as a fellow
Ashish Kumar
1 paper
Benjamin Mizukawa
1 paper
Brian Turpin
1 paper
Erin Breese
1 paper
James Daniero
1 paper

Clinical trials

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2033
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030